Stoke Therapeutics Inc (STOK) - Total Assets
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) holds total assets worth $443.28 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Stoke Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Stoke Therapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Stoke Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Stoke Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Stoke Therapeutics Inc's total assets of $443.28 Million consist of 73.1% current assets and 26.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $7.91 Million | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Stoke Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Stoke Therapeutics Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Stoke Therapeutics Inc's current assets represent 73.1% of total assets in 2025, a decrease from 78.3% in 2017.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2025, down from 73.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Stoke Therapeutics Inc Competitors by Total Assets
Key competitors of Stoke Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Stoke Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.99 | 8.41 | 31.75 |
| Quick Ratio | 8.99 | 8.41 | 31.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $325.88 Million | $331.05 Million | $252.04 Million |
Stoke Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Stoke Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.75 |
| Latest Market Cap to Assets Ratio | 4.30 |
| Asset Growth Rate (YoY) | 54.1% |
| Total Assets | $418.43 Million |
| Market Capitalization | $1.80 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Stoke Therapeutics Inc's assets at a significant premium (4.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Stoke Therapeutics Inc's assets grew by 54.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Stoke Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $418.43 Million | +54.09% |
| 2024-12-31 | $271.56 Million | +18.92% |
| 2023-12-31 | $228.34 Million | -10.83% |
| 2022-12-31 | $256.07 Million | +7.20% |
| 2021-12-31 | $238.87 Million | -19.82% |
| 2020-12-31 | $297.93 Million | +30.24% |
| 2019-12-31 | $228.75 Million | +112.71% |
| 2018-12-31 | $107.54 Million | +4309.14% |
| 2017-12-31 | $2.44 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more